Investor Exit Highlights Challenges for Bayer Amid Legal and Pipeline Crossroads

The departure of a prominent activist investor has cast a spotlight on the ongoing pressures facing pharmaceutical and agrochemical giant Bayer. Jeff Ubben has exited his position, selling approximately 8.5 million shares at a price of €37.45 each through JPMorgan Chase. This transaction, valued at roughly €318 million, represents a loss of about 25% compared to his initial entry price. The market reaction was swift, with Bayer's stock declining by as much as 3.7% on the day.

UBS Maintains Bullish Stance Despite Setback

In contrast to this high-profile sell-off, analysts at UBS have reaffirmed their confidence in the company. Strategist Matthew Weston continues to rate the shares a "Buy," with a price target of €52. This target suggests a potential upside exceeding 30% from the current level near €38. Weston's optimism is partly predicated on an anticipated near-term resolution to the long-running glyphosate litigation. He also views the core business operations favorably, noting that pharmaceutical growth drivers Nubeqa and Kerendia are outperforming market expectations. Further medium-term momentum, he suggests, could come from the developmental drugs Asundexian and the menopause treatment Lynkuet.

Asundexian represents one of the most closely watched candidates in Bayer's development pipeline. In the Phase III OCEANIC-STROKE trial, this Factor XIa inhibitor demonstrated significant superiority over a placebo in preventing recurrent ischemic strokes. This marks the first successful study of its kind for this class of substance. Bayer intends to approach regulatory authorities based on this data; the U.S. Food and Drug Administration has already granted the drug Fast-Track designation.

Should investors sell immediately? Or is it worth buying Bayer?

A Pivotal Period on the Calendar

The end of April shapes up as a critical juncture for the company. The Annual General Meeting is scheduled for April 24. Key agenda items include the discharge of the Management Board, the election of new Supervisory Board members Marcel Smits and Alfred Stern, and a proposed dividend of €0.11 per share. The decision to maintain the dividend at the previous year's level—despite a net loss of €3.62 billion and a net financial debt of approximately €29.8 billion—highlights the constrained financial flexibility Bayer is currently navigating.

Just three days later, on April 27, oral arguments will commence before the U.S. Supreme Court in the case of Monsanto v. Durnell. The core legal question is whether federal law preempts state-level lawsuits concerning the alleged absence of cancer warnings on glyphosate-based products. Bayer has received backing from the U.S. Department of Justice, which filed a brief in support of the company. A ruling is expected in the second half of June. The outcome could provide a foundation for reassessing the multi-billion euro legal liabilities that have burdened Bayer for years. The company will then report its first-quarter 2026 financial results on May 12.

Ad

Bayer Stock: New Analysis - 30 March

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

DE000BAY0017 | INVESTOR | boerse | 69027090 |